Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for DURAVYU (EYP-1901) in Diabetic macular edema (DME). The expected timing is based on the latest available company guidance and may change.
VERONA trial. 1/10/24- First patient dosed. 6/26/24- Completed enrollment. 2/5/25- Reported 6mth results, met primary endpoint. 8/6/25- 24wk end of study results at The Retina Society. 10/14/25- Initiated pivotal Ph3 trial with first patient dosing in Q1 2026. 11/05/25:- Confirmed pivotal Ph3 DME program with COMO and CAPRI trials, with first patient dosing expected in Q1 2026. Additional VERONA Ph2 and new mechanistic data were presented at multiple 2025 meetings. 03/02/26:- First patient dosed in Ph3 COMO and CAPRI DME trials; topline data anticipated in H2 2027. 03/04/26:- COMO and CAPRI Ph3 DME trials active; enrollment ongoing; topline data expected in H2 2027. 05/06/26:- COMO/CAPRI over one-third enrolled; full enrollment expected Q3 2026; topline DME data anticipated Q4 2027. 07/30/26:- Completed COMO/CAPRI enrollment; topline 56-week DME data expected Q4 2027. 08/05/26:- COMO/CAPRI enrolled over 480 patients. Topline data expected Q4 2027.
Verification
Confirm timing and program details against the company announcement or filing.